Food-drug Interaction Clinical Trial
Official title:
Licorice Botanical Dietary Supplements - Metabolism and Safety in Women
Verified date | May 2023 |
Source | University of Illinois at Chicago |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Human safety studies will be carried out to test whether red clover botanical dietary supplements used by peri- and post-menopausal women are safe to use with Food and Drug Administration (FDA)-approved drugs. To test this, a red clover dietary supplement (previously tested in women at the University of Illinois at Chicago without any harmful effects) will be given with four selected FDA-approved drugs to determine if the Licorice supplement can increase or decrease how these medications are absorbed, metabolized and excreted by the human body. Preclinical studies predict that the licorice supplement might affect the metabolism or break down of these probe drugs.
Status | Completed |
Enrollment | 19 |
Est. completion date | April 22, 2022 |
Est. primary completion date | July 31, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 40 Years to 79 Years |
Eligibility | Inclusion Criteria: - healthy peri- and post-menopausal women ages 40 - 79 - non-smokers - no-significant medical conditions as assessed by subject-reported medical history, physical examination and blood and urine chemistry screens - no medical condition that requires chronic use of medication Exclusion Criteria: - known allergies or hypersensitivity to caffeine, dextromethorphan, sulfonylureas (tolbutamide), benzodiazepines, or licorice - positive pregnancy test - use of hormone therapy within 8 weeks of study initiation for oral agents, 4 weeks for transdermal or other topical agents - use of caffeine products 7 days before study participation or during the study - use of citrus products 7 days before study participation or during the study - other prescription (with the exception of the Mirena® IUD) or non-prescription medicines within the 2 weeks prior to study initiation or during the study - chronic diseases, such as inflammatory bowel disease, that could alter the absorption or metabolism of the probe substrates - unwillingness to comply with study requirements - current participation in another clinical trial - CYP2D6 deficiency based on phenotyping at screening - smoker - licorice (whether as a botanical dietary supplement, candy, food, drink or otherwise) within the previous two weeks and during the study - use of any dietary supplements within the last 2 weeks prior to study initiation and during the study - extreme obesity (defined as >40 BMI) - alcohol or drug abuse - chronic diseases such as diabetes. |
Country | Name | City | State |
---|---|---|---|
United States | University of Illinois at Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
University of Illinois at Chicago | Oregon State University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1. Area Under the Curve (AUC) | Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate area under the (extrapolated) concentration-time curve to determine any changes compared to pre-intervention. | baseline and 14 days | |
Secondary | 1. Apparent Clearance | Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate apparent clearance of probe drug to determine any changes compared to pre-intervention. | baseline and 14 days | |
Secondary | 2. Peak Concentration | Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate peak concentration of probe drug to determine any changes compared to pre-intervention. | baseline and 14 days | |
Secondary | 3. Time for Peak Concentration | Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate time for peak concentration of probe drug to determine any changes compared to pre-intervention. | baseline and 14 days | |
Secondary | 4. Drug Half-life [Time Frame: baseline and 14 days] | Concentration of probe drugs from blood draws during the 14-day intervention will be used to calculate half-life of probe drug to determine any changes compared to pre-intervention. | baseline and 14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05533788 -
ABSK091 Food Effect Study in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04645940 -
Fruquintinib Food Effect and Proton Pump Inhibitor Study
|
Phase 1 | |
Completed |
NCT03205787 -
Red Clover Botanical Dietary Supplements - Metabolism and Safety in Women
|
N/A | |
Completed |
NCT01526213 -
Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?
|
N/A | |
Completed |
NCT06211283 -
Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT03215875 -
A Food Effect Study of 60mg ER Torsemide
|
Phase 1 | |
Completed |
NCT04303039 -
Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04397445 -
Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration
|
Phase 1 | |
Completed |
NCT04374981 -
Effect of Pineapple Juice on the Pharmacokinetics of Celecoxib and Montelukast in Humans
|
Phase 2 | |
Completed |
NCT04668274 -
JOTROL PK, Safety, and Food Effect Assessment
|
Phase 1 | |
Completed |
NCT03442621 -
Relacorilant Food Effect Study in Healthy Subjects
|
Phase 1 | |
Completed |
NCT05278845 -
Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects
|
Phase 1 | |
Recruiting |
NCT04673474 -
A Food-Effect Study of Hemay022 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT06218979 -
KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution
|
Phase 1 |